Published in Gene Therapy Weekly, September 19th, 2002
Monsanto had performed its obligations to deliver genes due under the contract, but Mycogen had sought a double recovery of full future damages in addition to delivery of the valuable gene technology.
"We're delighted that the California Supreme Court has concluded that the jury award was improper and that this litigation is at an end," said Robert T. Fraley, PhD, chief technology officer for Monsanto. "We hope this sets the stage for us to...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.